In accordance with the legislation of the Czech Republic, the Company provides services only to qualified investors!

Omega Therapeutics (OMGA) Financial results for the second quarter of 2021.

10.09.2021

GAAP net loss is -$3,36.

As of June 30, 2021 cash and cash equivalents are $122.4 million which does not include gross IPO income to the value of $141.1 million.